Every cell in your body runs on NAD⁺. It powers your mitochondria, repairs your DNA, and activates the longevity enzymes that slow biological aging — yet by your 40s, your levels may have already dropped by half.
Nicotinamide adenine dinucleotide (NAD⁺) is not a trend. It is a foundational coenzyme found in every living cell, orchestrating more than 500 enzymatic reactions. Its decline with age isn't just a curiosity of biology — it's increasingly understood as a central driver of the aging process itself. The emerging science around NAD⁺ restoration is reshaping how longevity-minded clinicians and researchers think about cellular health.
Why NAD⁺ Declines With Age
The loss of NAD⁺ is not a passive process. As we age, the enzymes that consume NAD⁺ — particularly PARP1 (triggered by DNA damage), CD38 (an immune-related enzyme), and SARM1 — grow increasingly active, drawing down cellular reserves faster than the body can replenish them. Research published in Cell Metabolism established that CD38 is a primary driver of age-related NAD⁺ decline, linking its overactivation to mitochondrial dysfunction via a SIRT3-dependent mechanism.[1]
The downstream effects are profound. When NAD⁺ is depleted, sirtuins — the so-called "longevity proteins" — lose their fuel. Mitochondria become less efficient. DNA repair slows. Cellular senescence accelerates. Research published in npj Aging confirms that systemic NAD⁺ decline is now broadly accepted as a key driving force of aging across multiple biological systems.[2]
The Longevity Benefits of NAD⁺ Restoration
The evidence base for NAD⁺ replenishment spans preclinical and an expanding body of human research. Here are the most well-supported areas of benefit:
NAD⁺ is the primary fuel for oxidative phosphorylation — the process by which mitochondria convert food into usable energy. Restoring NAD⁺ levels has been shown to enhance mitochondrial efficiency and counteract the energy deficits common in aging tissues.
PARP enzymes, which are critical for detecting and repairing DNA damage, are entirely dependent on NAD⁺ as a substrate. Adequate NAD⁺ availability ensures the body can respond to genomic stress — a cornerstone of cancer prevention and cellular longevity.[3]
NAD⁺ decline in brain tissue has been observed in association with neurodegenerative conditions. A 2024 randomized controlled trial published in GeroScience investigated nicotinamide riboside (an NAD⁺ precursor) in older adults with mild cognitive impairment, with researchers noting improvements in neurological markers.[4]
A 2021 study in healthy adults found that NMN supplementation increased clamp-derived muscle insulin sensitivity by 25% from baseline — a meaningful metabolic marker. Muscle NAD⁺ decline is linked to sarcopenia, the age-related loss of muscle mass and strength.[5]
Sirtuins (SIRT1–SIRT7) are NAD⁺-dependent enzymes linked to longevity across species. They regulate inflammation, stress resistance, and metabolic homeostasis. Higher NAD⁺ availability directly amplifies sirtuin activity — the biological equivalent of turning up the longevity dial.
Restoring NAD⁺ levels has been associated with reductions in pro-inflammatory cytokines — including IL-2 — and a shift in immune glycosylation patterns toward a biologically younger profile, according to a double-blind crossover trial in npj Aging.[6]
NAD⁺ isn't one piece of the aging puzzle — it's the molecule that holds the pieces together. When it falls, everything downstream follows.Synthesized from current longevity research
Why Delivery Matters: The Case for IV
Not all NAD⁺ arrives where it's needed. This is the critical distinction between oral supplementation and intravenous therapy — and it has significant implications for therapeutic outcomes.
Oral supplements don't actually contain NAD⁺ itself. The molecule is too large for effective intestinal absorption, so oral products use precursors — nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN) — which the body must then convert to NAD⁺ through multiple enzymatic steps. This conversion process is subject to first-pass liver metabolism, gut microbiome variability, and the declining enzymatic efficiency of aging — meaning the amount that actually reaches cellular NAD⁺ pools is a fraction of what was taken.[7]
IV NAD⁺ therapy bypasses these bottlenecks entirely. Delivered directly into the bloodstream, every molecule is immediately bioavailable — achieving therapeutic plasma concentrations that oral supplementation simply cannot match. For those with pre-existing NAD⁺ depletion, metabolic stress, or age-related conversion inefficiency, this difference is clinically meaningful.
*Blood NAD+ increase from oral NR/NMN; intracellular conversion variable by individual. Sources: medRxiv 2024, South Lake Pharmacy 2026
A 2024 pilot clinical trial published on medRxiv specifically compared intravenous NR, NAD⁺ IV, oral NR, and placebo — finding that intravenous administration bypasses "gastrointestinal digestive enzyme- and microbiota-mediated degradation and hepatic first-pass metabolism," potentially exerting a more potent impact on systemic NAD⁺ levels.[8] Clinically, IV-delivered NAD⁺ is well established in settings ranging from addiction medicine to neurological support and fatigue recovery.
The ideal protocol for most patients combines an initial IV loading series — typically administered over several sessions to reach therapeutic levels — followed by subcutaneous injections or targeted oral supplementation for maintenance. This layered approach respects both the science of bioavailability and the practical reality of long-term compliance.
Who Should Consider NAD⁺ Therapy
NAD⁺ restoration is particularly relevant for adults over 35 noticing changes in energy, recovery, mental clarity, or body composition. It is also gaining traction as a proactive intervention in healthy individuals who want to maintain cellular function before depletion becomes symptomatic. Athletes, executives under chronic stress, those recovering from illness, and anyone serious about longevity medicine are natural candidates for a medically supervised protocol.
As with any therapeutic intervention, baseline NAD⁺ testing, individual health history, and clinical guidance are essential. The science is compelling — but optimal outcomes depend on precision, not guesswork.
Research References
- Camacho-Pereira J, et al. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through a SIRT3-Dependent Mechanism. Cell Metabolism. 2016. PubMed →
- Imai SI. NAD World 3.0: the importance of the NMN transporter and eNAMPT in mammalian aging and longevity control. npj Aging. 2025. Nature →
- PMC Review: Promising Results With NAD Supplementation in Rare Diseases With Premature Aging and DNA Damage. 2025. PMC →
- Orr ME, et al. A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment. GeroScience. 2024. DOI →
- Yoshino M, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021. Cited in ScienceDirect 2026 PRISMA review →
- Dolopikou CF, et al. Systems approach NAD+ supplementation (Nuchido TIME+) increases SIRT1, reduces IL-2, and shifts IgG glycosylation toward younger profile. npj Aging. 2024. Nature →
- Radenkovic D, Reason, Verdin E. Clinical Evidence for Targeting NAD Therapeutically. Pharmaceuticals. 2020. PMC →
- Pilot RCT: IV NR vs NAD+ IV vs Oral NR vs Placebo in healthy adults. medRxiv. 2024. medRxiv →
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. NAD⁺ therapy should only be pursued under the supervision of a licensed healthcare provider. Claims regarding benefits are based on current research and may not apply universally. Always consult a qualified physician before beginning any new treatment.